Evaluación de la eficacia de la eritropoyetina en el tratamiento de la anemia en pacientes con enfermedad renal crónica sometidos a hemodiálisis
Fecha
2024
Autores
Asesor
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad Nacional San Luis Gonzaga
Resumen
Analizar la eficacia de la eritropoyetina en el tratamiento de la anemia en los
pacientes con enfermedad renal crónica sometidos a hemodiálisis
Estrategia metodológica: Estudio cuantitativo, diseño no experimental, descriptivo.
Historias clínicas y documentos complementarios de pacientes que acuden para su atención
en un clínica particular de diálisis. Técnica, análisis documental. Se tomó en cuenta las
historias clínicas y documentos complementarios de 52 personas adultas que acudieron para
su atención a la clínica particular de diálisis, se determinó por muestreo probalístico
sistemático
Resultados y conclusiones: El promedio de edad de los pacientes hemodializados es de
59,36 años, la mediana es de 62,5 años, la moda es de 65 años. El rango de edades es de 46,
considerando que el participante de menor edad tenía 37años y el participante de mayor edad
83 años. según dosaje de hemoglobina, el 19.2%, tenía 10 g/dL o menos(8,1% - 10,0 g/dL)
en la etapa pre EPO y el 80,8% tenía más de 10 g/dL (10,3% - 11,2 g/dL). En la etapa pos
EPO, el 13,5% presentaron valores de 10 g/dL o menos (9,0% - 9,6 g/dL) y el 86,5% tenía
más de 10 g/dL (11,0% - 12,5 g/dL). Según dosaje de hierro sérico, se tiene que el 86,5%,
tenía 100 mcg/dL o menos (46,97 – 98,4 mcg/dL) en la etapa pre EPO y el 13,5% tenía más
de 100 mg/dL (110 – 120,6 mcg/dL). En la etapa pos EPO, el 80,8% presentaron valores de
100 mcg/dL o menos (55 - 92 mcg/dL) y el 19,2% tenía más de 100 mg/dL (104 – 200
mcg/dL).
To analyze the efficacy of erythropoietin in the treatment of anemia in patients with chronic kidney disease undergoing hemodialysis. Methodological Strategy: Quantitative study, non-experimental, descriptive design. Medical records and complementary documents of patients receiving care at a private dialysis clinic were analyzed. The technique used was documentary analysis. The medical records and complementary documents of 52 adult patients who received care at the private dialysis clinic were included, determined by systematic probabilistic sampling. Results and Conclusions: The average age of the hemodialysis patients was 59.36 years, the median age was 62.5 years, and the mode was 65 years. The age range was 46 years, with the youngest participant being 37 years old and the oldest 83 years old. According to hemoglobin levels, 19.2% had 10 g/dL or less (8.1% - 10.0 g/dL) in the pre-EPO stage, and 80.8% had more than 10 g/dL (10.3% - 11.2 g/dL). In the post-EPO stage, 13.5% had values of 10 g/dL or less (9.0% - 9.6 g/dL), and 86.5% had more than 10 g/dL (11.0% - 12.5 g/dL). According to serum iron levels, 86.5% had 100 mcg/dL or less (46.97 – 98.4 mcg/dL) in the pre-EPO stage, and 13.5% had more than 100 mg/dL (110 – 120.6 mcg/dL). In the post-EPO stage, 80.8% had values of 100 mcg/dL or less (55 - 92 mcg/dL), and 19.2% had more than 100 mg/dL (104 – 200 mcg/dL).
To analyze the efficacy of erythropoietin in the treatment of anemia in patients with chronic kidney disease undergoing hemodialysis. Methodological Strategy: Quantitative study, non-experimental, descriptive design. Medical records and complementary documents of patients receiving care at a private dialysis clinic were analyzed. The technique used was documentary analysis. The medical records and complementary documents of 52 adult patients who received care at the private dialysis clinic were included, determined by systematic probabilistic sampling. Results and Conclusions: The average age of the hemodialysis patients was 59.36 years, the median age was 62.5 years, and the mode was 65 years. The age range was 46 years, with the youngest participant being 37 years old and the oldest 83 years old. According to hemoglobin levels, 19.2% had 10 g/dL or less (8.1% - 10.0 g/dL) in the pre-EPO stage, and 80.8% had more than 10 g/dL (10.3% - 11.2 g/dL). In the post-EPO stage, 13.5% had values of 10 g/dL or less (9.0% - 9.6 g/dL), and 86.5% had more than 10 g/dL (11.0% - 12.5 g/dL). According to serum iron levels, 86.5% had 100 mcg/dL or less (46.97 – 98.4 mcg/dL) in the pre-EPO stage, and 13.5% had more than 100 mg/dL (110 – 120.6 mcg/dL). In the post-EPO stage, 80.8% had values of 100 mcg/dL or less (55 - 92 mcg/dL), and 19.2% had more than 100 mg/dL (104 – 200 mcg/dL).
Descripción
Palabras clave
Hemodiálisis, Hemoglobina, Enfermedad renal crónica, Hemodialysis